Related references
Note: Only part of the references are listed.Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes
Cristina B. Guzman et al.
DIABETES OBESITY & METABOLISM (2017)
Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult participants in the T1D exchange clinic registry
Mark A. Clements et al.
PEDIATRIC DIABETES (2016)
Glucagon therapeutics: Dawn of a new era for diabetes care
Jaime A. Davidson et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2016)
Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway
May-Yun Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Roger H. Unger et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Meena Asmar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Hypoglycemia in Type 1 Diabetes
Rory J. McCrimmon et al.
DIABETES (2010)
Homozygous P86S Mutation of the Human Glucagon Receptor Is Associated With Hyperglucagonemia, α Cell Hyperplasia, and Islet Cell Tumor
Cuiqi Zhou et al.
PANCREAS (2009)
Paradoxical stimulation of glucagon secretion by high glucose concentrations
Albert Salehi et al.
DIABETES (2006)
Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice
RW Gelling et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type I diabetes
MS Fineman et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Share Paper
